 | • レポートコード：QY20ST-06993 • 出版社/出版日：QYResearch / 2020年9月15日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥560,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥840,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,120,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界の肝性脳症治療薬市場について種類別（注射、経口）、用途別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・肝性脳症治療薬市場の概要 ・世界の主要地域別肝性脳症治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の肝性脳症治療薬市場規模2015-2026：種類別（注射、経口） ・世界の肝性脳症治療薬市場規模2015-2026：用途別（病院薬局、小売薬局、オンライン薬局） ・肝性脳症治療薬の北米市場規模2015-2020 ・肝性脳症治療薬のヨーロッパ市場規模2015-2020 ・肝性脳症治療薬の中国市場規模2015-2020 ・肝性脳症治療薬の日本市場規模2015-2020 ・肝性脳症治療薬の東南アジア市場規模2015-2020 ・肝性脳症治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・肝性脳症治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・肝性脳症治療薬の市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Hepatic Encephalopathy Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Hepatic Encephalopathy Drugs market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets & solutions) and injections.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Hepatic Encephalopathy Drugs market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Hepatic Encephalopathy Drugs industry.
Based on our recent survey, we have several different scenarios about the Hepatic Encephalopathy Drugs YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Hepatic Encephalopathy Drugs will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Hepatic Encephalopathy Drugs market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Hepatic Encephalopathy Drugs market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Hepatic Encephalopathy Drugs market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Hepatic Encephalopathy Drugs market. The report also includes nautical information, where it shows Hepatic Encephalopathy Drugs market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Hepatic Encephalopathy Drugs market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Hepatic Encephalopathy Drugs market.
Geographical Analysis:
Based on region, the global Hepatic Encephalopathy Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Hepatic Encephalopathy Drugs market are
ASKA Pharmaceutical
Cosmo Pharmaceuticals
Bausch Health
Ferring Pharmaceuticals
Mallinckrodt
Umecrine Cognition
Norgine
Lupin
Kaleido Biosciences
Kannalife Sciences
Segment by Type
Injection
Oral
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Hepatic Encephalopathy Drugs market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Hepatic Encephalopathy Drugs market.
• The market share of the global Hepatic Encephalopathy Drugs market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Hepatic Encephalopathy Drugs market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Hepatic Encephalopathy Drugs market.
1 Hepatic Encephalopathy Drugs Market Overview
1.1 Hepatic Encephalopathy Drugs Product Scope
1.2 Hepatic Encephalopathy Drugs Segment by Type
1.2.1 Global Hepatic Encephalopathy Drugs Sales by Type (2020-2026)
1.2.2 Injection
1.2.3 Oral
1.3 Hepatic Encephalopathy Drugs Segment by Application
1.3.1 Global Hepatic Encephalopathy Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Hepatic Encephalopathy Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Hepatic Encephalopathy Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Hepatic Encephalopathy Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Hepatic Encephalopathy Drugs Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Hepatic Encephalopathy Drugs Industry Impact
1.5.1 How the Covid-19 is Affecting the Hepatic Encephalopathy Drugs Industry
1.5.1.1 Hepatic Encephalopathy Drugs Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Hepatic Encephalopathy Drugs Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Hepatic Encephalopathy Drugs Players to Combat Covid-19 Impact
2 Hepatic Encephalopathy Drugs Estimate and Forecast by Region
2.1 Global Hepatic Encephalopathy Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Hepatic Encephalopathy Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Hepatic Encephalopathy Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Hepatic Encephalopathy Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Hepatic Encephalopathy Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Hepatic Encephalopathy Drugs Estimates and Projections (2015-2026)
2.4.3 China Hepatic Encephalopathy Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Hepatic Encephalopathy Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Hepatic Encephalopathy Drugs Estimates and Projections (2015-2026)
2.4.6 India Hepatic Encephalopathy Drugs Estimates and Projections (2015-2026)
3 Global Hepatic Encephalopathy Drugs Competition Landscape by Players
3.1 Global Top Hepatic Encephalopathy Drugs Players by Sales (2015-2020)
3.2 Global Top Hepatic Encephalopathy Drugs Players by Revenue (2015-2020)
3.3 Global Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy Drugs as of 2019)
3.4 Global Hepatic Encephalopathy Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Hepatic Encephalopathy Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Hepatic Encephalopathy Drugs Players (Opinion Leaders)
4 Global Hepatic Encephalopathy Drugs Market Size by Type
4.1 Global Hepatic Encephalopathy Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Hepatic Encephalopathy Drugs Price by Type (2014-2020)
4.2 Global Hepatic Encephalopathy Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Hepatic Encephalopathy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hepatic Encephalopathy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Hepatic Encephalopathy Drugs Price Forecast by Type (2021-2026)
5 Global Hepatic Encephalopathy Drugs Market Size by Application
5.1 Global Hepatic Encephalopathy Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Hepatic Encephalopathy Drugs Price by Application (2015-2020)
5.2 Global Hepatic Encephalopathy Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Hepatic Encephalopathy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hepatic Encephalopathy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hepatic Encephalopathy Drugs Price Forecast by Application (2021-2026)
3 North America Hepatic Encephalopathy Drugs Market Facts & Figures
3.2 North America Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
3.3 North America Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
3.4 North America Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
4 Europe Hepatic Encephalopathy Drugs Market Facts & Figures
4.2 Europe Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
4.3 Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
4.4 Europe Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
5 China Hepatic Encephalopathy Drugs Market Facts & Figures
5.2 China Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
5.3 China Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
5.4 China Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
6 Japan Hepatic Encephalopathy Drugs Market Facts & Figures
6.2 Japan Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
6.3 Japan Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
6.4 Japan Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
7 Southeast Asia Hepatic Encephalopathy Drugs Market Facts & Figures
7.2 Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
8 India Hepatic Encephalopathy Drugs Market Facts & Figures
8.2 India Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
8.3 India Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
8.4 India Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Hepatic Encephalopathy Drugs Business
12.1 ASKA Pharmaceutical
12.1.1 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Corporation Information
12.1.2 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Products Offered
12.1.5 ASKA Pharmaceutical Recent Development
12.2 Cosmo Pharmaceuticals
12.2.1 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Corporation Information
12.2.2 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.2.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Products Offered
12.2.5 Cosmo Pharmaceuticals Recent Development
12.3 Bausch Health
12.3.1 Bausch Health Hepatic Encephalopathy Drugs Corporation Information
12.3.2 Bausch Health Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.3.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Bausch Health Hepatic Encephalopathy Drugs Products Offered
12.3.5 Bausch Health Recent Development
12.4 Ferring Pharmaceuticals
12.4.1 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Corporation Information
12.4.2 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.4.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Products Offered
12.4.5 Ferring Pharmaceuticals Recent Development
12.5 Mallinckrodt
12.5.1 Mallinckrodt Hepatic Encephalopathy Drugs Corporation Information
12.5.2 Mallinckrodt Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.5.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Mallinckrodt Hepatic Encephalopathy Drugs Products Offered
12.5.5 Mallinckrodt Recent Development
12.6 Umecrine Cognition
12.6.1 Umecrine Cognition Hepatic Encephalopathy Drugs Corporation Information
12.6.2 Umecrine Cognition Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.6.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Umecrine Cognition Hepatic Encephalopathy Drugs Products Offered
12.6.5 Umecrine Cognition Recent Development
12.7 Norgine
12.7.1 Norgine Hepatic Encephalopathy Drugs Corporation Information
12.7.2 Norgine Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.7.3 Norgine Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Norgine Hepatic Encephalopathy Drugs Products Offered
12.7.5 Norgine Recent Development
12.8 Lupin
12.8.1 Lupin Hepatic Encephalopathy Drugs Corporation Information
12.8.2 Lupin Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.8.3 Lupin Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Lupin Hepatic Encephalopathy Drugs Products Offered
12.8.5 Lupin Recent Development
12.9 Kaleido Biosciences
12.9.1 Kaleido Biosciences Hepatic Encephalopathy Drugs Corporation Information
12.9.2 Kaleido Biosciences Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.9.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Products Offered
12.9.5 Kaleido Biosciences Recent Development
12.10 Kannalife Sciences
12.10.1 Kannalife Sciences Hepatic Encephalopathy Drugs Corporation Information
12.10.2 Kannalife Sciences Hepatic Encephalopathy Drugs Business Overview and Total Revenue
12.10.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Kannalife Sciences Hepatic Encephalopathy Drugs Products Offered
12.10.5 Kannalife Sciences Recent Development
13 Hepatic Encephalopathy Drugs Manufacturing Cost Analysis
13.1 Hepatic Encephalopathy Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Hepatic Encephalopathy Drugs
13.4 Hepatic Encephalopathy Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Hepatic Encephalopathy Drugs Distributors List
14.3 Hepatic Encephalopathy Drugs Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Hepatic Encephalopathy Drugs Sales (MT) Growth Rate by Type (2020-2026)
Table 2. Global Hepatic Encephalopathy Drugs Sales (MT) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Hepatic Encephalopathy Drugs Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Hepatic Encephalopathy Drugs Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Hepatic Encephalopathy Drugs Players to Combat Covid-19 Impact
Table 8. Global Market Hepatic Encephalopathy Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Hepatic Encephalopathy Drugs Sales (MT) by Region (2015-2020)
Table 10. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2015-2020)
Table 11. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Hepatic Encephalopathy Drugs Revenue Share by Region (2015-2020)
Table 13. Global Hepatic Encephalopathy Drugs Sales (MT) Forecast by Region (2021-2026)
Table 14. Global Hepatic Encephalopathy Drugs Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Hepatic Encephalopathy Drugs Revenue Share Forecast by Region (2021-2026)
Table 17. Global Hepatic Encephalopathy Drugs (MT) of Key Companies (2015-2020)
Table 18. Global Hepatic Encephalopathy Drugs Sales Share by Company (2015-2020)
Table 19. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Hepatic Encephalopathy Drugs Revenue Share by Company (2015-2020)
Table 21. Global Hepatic Encephalopathy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy Drugs as of 2019)
Table 22. Global Hepatic Encephalopathy Drugs Average Price (USD/Kg) of Key Company (2015-2020)
Table 23. Manufacturers Hepatic Encephalopathy Drugs Manufacturing Sites and Area Served
Table 24. Manufacturers Hepatic Encephalopathy Drugs Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Hepatic Encephalopathy Drugs Players
Table 27. Global Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 28. Global Hepatic Encephalopathy Drugs Sales Share by Type (2015-2020)
Table 29. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Hepatic Encephalopathy Drugs Price (MT) by Type (2015-2020)
Table 31. Global Hepatic Encephalopathy Drugs Sales Share by Type (2021-2026)
Table 32. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2021-2026)
Table 34. Global Hepatic Encephalopathy Drugs Price (MT) by Type (2021-2026)
Table 35. Global Hepatic Encephalopathy Drugs Sales (MT) by Application (2015-2020)
Table 36. Global Hepatic Encephalopathy Drugs Sales Share by Application (2015-2020)
Table 37. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Hepatic Encephalopathy Drugs Price (MT) by Application (2015-2020)
Table 39. Global Hepatic Encephalopathy Drugs Sales (MT) by Application (2021-2026)
Table 40. Global Hepatic Encephalopathy Drugs Sales Share by Application (2021-2026)
Table 41. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2021-2026)
Table 43. Global Hepatic Encephalopathy Drugs Price (MT) by Application (2021-2026)
Table 44. United States Hepatic Encephalopathy Drugs Sales (MT) by Company (2015-2020)
Table 45. United States Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
Table 46. United States Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 47. United States Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 48. United States Hepatic Encephalopathy Drugs Sales (MT) by Application (2015-2020)
Table 49. United States Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
Table 50. Europe Hepatic Encephalopathy Drugs Sales (MT) by Company (2015-2020)
Table 51. Europe Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
Table 52. Europe Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 53. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 54. Europe Hepatic Encephalopathy Drugs Sales (MT) by Application (2015-2020)
Table 55. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 56. China Hepatic Encephalopathy Drugs Sales (MT) by Company (2015-2020)
Table 57. China Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
Table 58. China Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 59. China Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 60. China Hepatic Encephalopathy Drugs Sales (MT) by Application (2015-2020)
Table 61. China Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
Table 62. Japan Hepatic Encephalopathy Drugs Sales (MT) by Company (2015-2020)
Table 63. Japan Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
Table 64. Japan Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 65. Japan Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 66. Japan Hepatic Encephalopathy Drugs Sales (MT) by Application (2015-2020)
Table 67. Japan Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Hepatic Encephalopathy Drugs Sales (MT) by Company (2015-2020)
Table 69. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 71. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 73. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
Table 74. India Hepatic Encephalopathy Drugs Sales (MT) by Company (2015-2020)
Table 75. India Hepatic Encephalopathy Drugs Sales Market Share by Company (2015-2020)
Table 76. India Hepatic Encephalopathy Drugs Sales (MT) by Type (2015-2020)
Table 77. India Hepatic Encephalopathy Drugs Sales Market Share by Type (2015-2020)
Table 78. India Hepatic Encephalopathy Drugs Sales (MT) by Application (2015-2020)
Table 79. India Hepatic Encephalopathy Drugs Sales Market Share by Application (2015-2020)
Table 80. ASKA Pharmaceutical Corporation Information
Table 81. ASKA Pharmaceutical Description and Business Overview
Table 82. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 83. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product
Table 84. ASKA Pharmaceutical Recent Development
Table 85. Cosmo Pharmaceuticals Corporation Information
Table 86. Cosmo Pharmaceuticals Description and Business Overview
Table 87. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 88. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product
Table 89. Cosmo Pharmaceuticals Recent Development
Table 90. Bausch Health Corporation Information
Table 91. Bausch Health Description and Business Overview
Table 92. Bausch Health Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 93. Bausch Health Hepatic Encephalopathy Drugs Product
Table 94. Bausch Health Recent Development
Table 95. Ferring Pharmaceuticals Corporation Information
Table 96. Ferring Pharmaceuticals Description and Business Overview
Table 97. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 98. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product
Table 99. Ferring Pharmaceuticals Recent Development
Table 100. Mallinckrodt Corporation Information
Table 101. Mallinckrodt Description and Business Overview
Table 102. Mallinckrodt Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 103. Mallinckrodt Hepatic Encephalopathy Drugs Product
Table 104. Mallinckrodt Recent Development
Table 105. Umecrine Cognition Corporation Information
Table 106. Umecrine Cognition Description and Business Overview
Table 107. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 108. Umecrine Cognition Hepatic Encephalopathy Drugs Product
Table 109. Umecrine Cognition Recent Development
Table 110. Norgine Corporation Information
Table 111. Norgine Description and Business Overview
Table 112. Norgine Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 113. Norgine Hepatic Encephalopathy Drugs Product
Table 114. Norgine Recent Development
Table 115. Lupin Corporation Information
Table 116. Lupin Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 117. Lupin Description and Business Overview
Table 118. Lupin Hepatic Encephalopathy Drugs Product
Table 119. Lupin Recent Development
Table 120. Kaleido Biosciences Corporation Information
Table 121. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 122. Kaleido Biosciences Description and Business Overview
Table 123. Kaleido Biosciences Hepatic Encephalopathy Drugs Product
Table 124. Kaleido Biosciences Recent Development
Table . Kannalife Sciences Corporation Information
Table . Kannalife Sciences Description and Business Overview
Table . Kannalife Sciences Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table . Kannalife Sciences Hepatic Encephalopathy Drugs Product
Table . Kannalife Sciences Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Hepatic Encephalopathy Drugs Distributors List
Table 133. Hepatic Encephalopathy Drugs Customers List
Table 134. Market Key Trends
Table 135. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 136. Key Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatic Encephalopathy Drugs Product Picture
Figure 2. Global Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Hepatic Encephalopathy Drugs Market Share by Application in 2020 & 2026
Figure 6. Hospital Pharmacies Examples
Figure 7. Retail Pharmacies Examples
Figure 8. Online Pharmacies Examples
Figure 9. Global Hepatic Encephalopathy Drugs Sales (MT) Growth Rate (2015-2026)
Figure 10. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Hepatic Encephalopathy Drugs Price Trends Growth Rate (2015-2026) (USD/Kg)
Figure 12. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Hepatic Encephalopathy Drugs Sales (MT) Growth Rate (2015-2026)
Figure 16. Europe Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Hepatic Encephalopathy Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Hepatic Encephalopathy Drugs Players Market Share by Revenue in Hepatic Encephalopathy Drugs 2015 & 2019
Figure 27. Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2015-2020)
Figure 29. Global Hepatic Encephalopathy Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2015-2020)
Figure 31. Global Hepatic Encephalopathy Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 33. United States Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 34. Europe Hepatic Encephalopathy Drugs Sales Market Share by Company in 2019
Figure 35. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 36. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application in 2019
Figure 37. China Hepatic Encephalopathy Drugs Sales Market Share by Company in 2019
Figure 38. China Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 39. China Hepatic Encephalopathy Drugs Sales Market Share by Application in 2019
Figure 40. Japan Hepatic Encephalopathy Drugs Sales Market Share by Company in 2019
Figure 41. Japan Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 42. Japan Hepatic Encephalopathy Drugs Sales Market Share by Application in 2019
Figure 43. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Company in 2019
Figure 44. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 45. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Application in 2019
Figure 46. India Hepatic Encephalopathy Drugs Sales Market Share by Company in 2019
Figure 47. India Hepatic Encephalopathy Drugs Sales Market Share by Type in 2019
Figure 48. India Hepatic Encephalopathy Drugs Sales Market Share by Application in 2019
Figure 49. ASKA Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Cosmo Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Bausch Health Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Ferring Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Mallinckrodt Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Umecrine Cognition Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Norgine Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Lupin Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Kaleido Biosciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Kannalife Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Key Raw Materials Price Trend
Figure 60. Manufacturing Cost Structure of Hepatic Encephalopathy Drugs
Figure 61. Manufacturing Process Analysis of Hepatic Encephalopathy Drugs
Figure 62. Hepatic Encephalopathy Drugs Industrial Chain Analysis
Figure 63. Channels of Distribution
Figure 64. Distributors Profiles
Figure 65. Porter's Five Forces Analysis
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
変形性関節症薬の世界市場レポート2020 A recently published report by QY Research titled Global Osteoarthritis Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accura…- 皮膚炎薬の世界市場レポート2020 A recently published report by QY Research titled Global Dermatitis Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate d…
- 抗線維化薬の世界市場レポート2020 A recently published report by QY Research titled Global Antifibrotic Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate…
- 腎臓用治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Renal Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- オープンアングル緑内障薬の世界市場レポート2020 A recently published report by QY Research titled Global Open Angle Glaucoma Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides a…